These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8116134)

  • 1. Experience in advanced prostatic cancer: orchiectomy and flutamide versus orchiectomy and estramustine phosphate.
    Roessler W; Hinke A; Wieland WF
    Urology; 1994 Feb; 43(2 Suppl):57-60. PubMed ID: 8116134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group.
    Janknegt RA; Boon TA; van de Beek C; Grob P
    Urology; 1997 Mar; 49(3):411-20. PubMed ID: 9123707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Complete androgen blockade (orchiectomy + flutamide) versus androgen blockade with cytostasis (orchiectomy + estramustine) in the treatment of virginal advanced prostate cancer].
    Flamm J; Fischer M
    Wien Klin Wochenschr; 1988 Sep; 100(17):589-92. PubMed ID: 3055689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinicopathological evaluation of etoposide or estramustine phosphate in castrated patients with advanced prostatic cancer].
    Matsuda H; Nonomura K; Nagamori S; Shinohara N; Koyanagi T; Maru A; Matsuno T; Fujieda J; Minami S; Morita H
    Nihon Hinyokika Gakkai Zasshi; 1995 Oct; 86(10):1530-7. PubMed ID: 7474602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies.
    Van de Voorde WM; Elgamal AA; Van Poppel HP; Verbeken EK; Baert LV; Lauweryns JM
    Cancer; 1994 Dec; 74(12):3164-75. PubMed ID: 7526970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.
    Denis LJ; Carnelro de Moura JL; Bono A; Sylvester R; Whelan P; Newling D; Depauw M
    Urology; 1993 Aug; 42(2):119-29; discussion 129-30. PubMed ID: 8367920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate.
    Johansson JE; Andersson SO; Beckman KW; Lingårdh G; Zador G
    Urology; 1987 Jan; 29(1):55-9. PubMed ID: 3798631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The present role of estramustine phosphate in advanced prostate cancer.
    Van Poppel H; Baert L
    Prog Clin Biol Res; 1991; 370():323-41. PubMed ID: 1924466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
    Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
    N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estramustine phosphate combined with orchidectomy as first-line therapy in patients with prostate carcinoma. Effect of age on survival.
    Pelger RC; Lycklama A Nijeholt Ga; Zwinderman AH; Hamdy NA
    Cancer; 2002 May; 94(10):2596-601. PubMed ID: 12173326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer.
    Boccardo F; Decensi A; Guarneri D; Martorana G; Giberti C; Giuliani L
    Cancer Chemother Pharmacol; 1988; 22(2):172-4. PubMed ID: 3409448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer.
    de Kernion JN; Murphy GP; Priore R
    Urology; 1988 Apr; 31(4):312-7. PubMed ID: 3281365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
    Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
    Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).
    Iversen P
    Eur Urol; 1990; 18 Suppl 3():41-4. PubMed ID: 2151275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach.
    Ansari MS; Gupta NP; Hemal AK; Dogra PN; Seth A
    Int J Urol; 2004 Dec; 11(12):1092-6. PubMed ID: 15663681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.
    Noguchi M; Kakuma T; Uemura H; Nasu Y; Kumon H; Hirao Y; Moriya F; Suekane S; Matsuoka K; Komatsu N; Shichijo S; Yamada A; Itoh K
    Cancer Immunol Immunother; 2010 Jul; 59(7):1001-9. PubMed ID: 20146063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients. A Belgian multicenter study of 905 patients.
    Oosterlinck W; Casselman J; Mattelaer J; Van Velthoven R; Kurjatkin O; Schulman C
    Eur Urol; 1996; 30(4):458-63. PubMed ID: 8977067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone therapy of prostatic bone metastases.
    Huben RP
    Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.